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Introduction

Abstract

Lonidamine,
1-(2.4-dichlorobenzyl)-1-H-indazol3-carboxylic acid, is a novel anticancer
drug, which
has been undergoing
Phase I and Phase II clinical
trials by itself (Band et al. 1984: Evans et al. 1984:
Gulisano et al. 1987) and in conjunction
with radiotherapy (Cripps et al. 1988).
It is reported to act by
interfering with respiration
in the mitochondria
rather
than as a mitotic poison, like most other anticancer
drugs (Caputo and Silvestrini
1984).
Lonidamine
inhibits
aerobic
and anaerobic
lactate
production
(Floridi et al. 1981a,b;
De Martino
et al. 1984),
inhibits mitochondrially bound hexokinase
(De Martino
et al. 1984) and is reported to produce ultrastructural
changes in the mitochondria
and the plasma membrane (Floridi et al. 1981a,b; De Martino et al. 1984:
Arancia et al. 1988: Floridi et al. 1987).
Since lonidamine acts on the cell's metabolism
rather than cell division, it has the potential to cause
tumor regression in new ways. In addition, since the
treated
cells are in a weakened
state,
synergism
between
lonidamine
and ionizing
radiation,
hyperthermia.
or other chemotherapeutic
agents
is
possible
(Kim et al. 1984: Starace
et al. 1987:
Bagnato et al. 1987; Floridi et al. 1987: Hahn et al.
1984; Silvestrini et al. 1983: Kim et al. 1986).
Although
effects
of lonidamine
have been
reported
in a number
of cell systems,
it is not
effective in all (De Martino et al. 1984).
Thus, it is
important
to test various
types of tumor cells to
further understand
the mode of action of lonidamine.
Its effect on two human-tumor
cell lines, MOL T-4
and U-87 MG, are reported here.
We have used transmission
and scanning
electron
microscopes
to observe
the amount
of
structural
damage in MOL T-4 and U-87 MG glioma
cells immediately after lonidamine exposure and after a
short incubation
time.
The level of cell killing
induced by the drug has also been measured in order
to correlate survival with morphological changes.
It is
important
to observe
morphological
changes
after

Lonidami ne, 1-(2-4-dichlorobenzyl)-1-H-indazol3-carboxylic acid. is an anticancer
drug that has its
primary action on cellular metabolism
rather than cell
division.
Since lonidamine is not effective in all tumor cells, we have tested it in two human-tumor
cell
culture lines: MOL T-4, a T-leukemia and U-87 MG. a
glioma.
Lonidamine
exposure
of MOL T-4 cells at
50 µg/mL and pH 6.7 disrupted
the mitochondria
within 1 h of treatment.
The mitochondria
were
swollen and the cristae were disrupted.
When the
treated cells were re-incubated
in fresh medium at
pH 7.4 the mitochondria
rapidly returned
to their
normal morphology.
The U-87 MG glioma cells did
not show ultrastructural
disruption after 1-h treatment
with lonidamine at concentrations
up to 200 µg/mL
at pH 6.7
In the concentration
range of 25 µg/mL
to
200 µg/mL.
lonidamine
did not produce
any cell
killing in MOL T-4 after a 1-h exposure
at pH 7.4,
although the drug had some limited effectiveness
at
pH 6.7.
Compared
to sham-treated
controls,
long
exposures
to 100 µg/mL
of lonidamine
at pH 6.7
reduced survival in MOL T-4 to 92% and 53% after
6-h and 24-h exposures,
respectively.
Survival of U87 MG glioma cells was also strongly pH dependent,
a 2-h exposure
to 50 µg/mL lonidamine
at pH 7.4
did not cause cell death; however, survival dropped to
84% of the control at pH 6.65.
Key words:
lonidamine,
ultrastructure,
mitochondria,
morphology, hyperthermia,
cell killing, MOL T-4, glioma,
cancer therapy, tumor cells, U-87 MG.
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lonidamine exposure because it may become clinically
useful in conjunction with other drugs, heat or radiation. Thus identification of organelles, which are the
targets of lonidamine, will offer clues to its mode of
action and may suggest
further
combinations
of
treatments
to expand its use.
In addition,
different
cell types from different tissues may react differently
to the drug.
Therefore, it is important to build up a
body of experience
about
the morphological
and
toxicological effects of lonidamine.
The MOL T-4 cell line is derived from a T-cell
leukemia and has many interesting
properties:
it is
radiation-sensitive;
it has a large number of pycnotic
nuclei when it dies, similar to the characteristic
apoptotic
death seen in circulating
lymphocytes;
it
does not repair sublethal
damage; and it does not
show synergistic
cell killing by heat and radiation
{Raaphorst et al. 1983; Szekely and Lobreau 1985).
The apoptotic
death of MOL T-4 cells allows cell
killing to be measured by trypan blue dye exclusion or
flow cytometry
after radiation
or drug treatment
(Szekely et al. 1985).
The gliobastoma
cells, U-87 MG, are grade Ill
human astrocytoma
cells.
The morphology
and
growth characteristics
of glioma cell lines have been
studied extensively ( Collins et al. 1979, 1980).
Since
human gliomas are difficult to treat and are often
malignant
(De Ridder et al. 1987), agents such as
lonidamine, which may be useful on their own or with
radiation or hyperthermia,
may offer increased tumor
cell killing.
Materials

G. Peter

Raaphorst,

et al.

microscopy, the medium was supplemented with glutamine to 1.83 g/L, sodium pyruvate to 0.11 g/L and
5
glucose
to 4.5 g/L.
Cells were seeded
at 10
cells/T75
flask and were subcultured
weekly
by
trypsinization.
For SEM and TEM the cells were
6
grown to confluence
at approximately
3 x 10
cells /flask.
Lonidamine Treatment
For the MOL T-4 cells, T25 culture
flasks
containing 15 ml of medium were placed overnight in
incubators containing a humidified CO2 atmosphere
of
25% for pH 6. 7 and 5% for pH 7.4 to equilibrate
pH and temperature.
The pH was measured
with a
6
Markson 5650 pH meter.
The 5 x 10 cells were
pelleted from a stock culture and resuspended
in the
pH equilibrated
medium.
Lonidamine was added at
the test concentration
from a stock solution
at
10 mg/ml
in dimethyl
sulfoxide
{DMSO).
The
DMSO was used to increase
the solubility
of
lonidamine and decrease the amount of solvent added
to the culture media.
The flasks were then returned
to their respective incubators.
For the glioma cells, the pH was adjusted
by
adding HCI to the HEPES buffered medium before the
flasks with cells were placed
in an
incubator
containing a 2% CO 2 humidified atmosphere.
The pH
remained constant during the treatment.
N

Electron Microscopy
For scanning
electron
microscopy
{SEM),
lonidamine-treated
MOL T-4 cells were fixed by adding
3 ml of sample to 9 ml of 4% glutaraldehyde
in
Hank's buffer with 0.04 mol/L sucrose.
The fixation
time was 30 min. The sample was then rinsed twice
in Hank's buffer with 0.04 mol/L sucrose, and it was
allowed
to settle
on poly-L-lysine-coated
glass
coverslips. Since the U-87 MG cells grow attached
to
a surface,
they were grown and fixed on glass
coverslips
placed within the flasks.
Both types of
cells on the coverslips
were dehydrated
through
a
graded series of ethanol and then amyl acetate before
being critically point-dried with CO2 • Cells were viewed
in an ISi microscope operated at 15 kV.
For transmission electron microscopy {TEM), the
U-87 MG cells were scraped
off the flask.
The
MOL T-4 or U-87 MG cells were pelleted
from the
medium, and then fixed and dehydrated in acetone by
Hayat's {1972) rapid procedure, using Millonig's phosphate buffer before being embedded in Spurr's epoxy
mixture.
Gold sections were stained with 2% uranyl
acetate and Reynold's lead citrate,
and viewed in a
Philips EM 300 electron microscope at 80 kV.

And Methods

Cell Culture
The MOL T-4 cell line was established
by
Minowada et al. {1972). The cells resemble relatively
mature
T-lymphocytes;
they form rosettes
with
unsensitized
sheep red blood cells, and they carry
surface antigens present in normal human T-cells and
thymus
leukemia
{Minowada
et al. 1972; Szekely
et al. 19876).
MOL T-4 cells were grown
in RPMI 1640
medium containing 10% heat-inactivated
fetal bovine
serum.
They were maintained in suspension in loosely capped T75 Falcon plastic flasks at 37°C in a 5%
CO2 humidified atmosphere.
They were maintained
in
log-phase growth by subculturing
every 3 to 4 days
and their doubling time ranged from 24 h to 32 h.
5
They were seeded at 10 cells /T75 flask and grew to
6
approximately 2.5 x 10 cells/T75 flask at the time of
subculture.
The U-87 MG glioma cells grow as a monolayer
of epithelia-like cells in DME/F-12
medium with 15%
heat-inactivated
fetal bovine
serum,
and 10 mM
NaHC0 3 and 20 mM HEP ES buffering
in a 2% CO2
humidified
atmosphere.
For glioma cells used in

Cell Survival
MOL T-4 survival was measured
by either flow
cytometry, using a method developed for radiation and
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TABLE 1. MOL T-4
lonidamine exposure

glucocorticoid-induced
killing, or by trypan blue dye
exclusion (Szekely et al. 1985; 1987 a).
Briefly, for
try pan blue staining, one part of 1 % try pan blue in
distilled water was added to five parts of cells in
medium.
After a 5 min equilibration period, the cells
were scored under an optical microscope
and cells
that had taken up the stain were scored as dead
cells. For flow cytometry a 4 ml sample of MOL T-4
cells
in medium
was analysed
in an Ortho
Cytofluorograf
50 H interfaced
with a 2150 Data
General Micro Nova computer.
The flow rate was
approximately
200 cells/s.
A 0.8 mW He-Ne laser
was used as the light source.
Axial light-loss and
right-angle scatter were collected for analysis.
The
three-dimensional
scattergram
generated
by plotting
the axial light-loss versus the right-angle scatter was
used to determine
the percentage
of live and dead
cells. Survival
was measured
at various
times
following the lonidamine
exposure.
Immediately
following the treatment,
the MOL T-4 cells were
resuspended in fresh medium and kept at pH 7.4 until
survival was measured.
The glioma
cells
were
plated
in dishes
immediately
following the drug exposure.
Survival
was determined by counting the number of colonies
produced by the treated cells, as previously described
(Raaphorst
and Azzam 1981).
Briefly, cells were
trypsinized
after treatment,
resuspended
in fresh
medium counted and plated at a concentration
chosen
to give approximately
10 to 150 colonies per dish.
Colonies were counted at 12 to 14 days after plating.
The plating efficiency averaged 27% for the series of
experiments.
Untreated controls were plated after exposure to media or media plus DMSO at the concentration used in the treatment
series.
No difference
was seen.

Treatment
Control

pH 7.4

Control

pH 6.7

5 µg/mL

survival

24

% Survival*
100
99 ±

h after

a 1-h

Number of
experiments
7

0.3

7

pH 6.7

95

1

25 µg/ml

pH 6.7

93

1

50 µg/ml

pH 6.7

97 ±

2.2

7

100 µg/mL

pH 6.7

85 ± 13.9

7

200 µg/mL

pH 6.7

90 ±

6

2.0

* Normalized to pH 7.4 control

systems lonidamine is much more effective
in cell
killing at low pH.
In clinical practice,
serum concentrations
of
10 µg/mL to 40 µg/ml
are found during treatments
that last for several days.
Since a 1-h exposure did
not produce much cell death, longer exposure times
were tried. Although longer exposures produced more
cell killing, (Tables 2 and 3), there still was a high
survival rate.
A 24-h exposure at 100 µg/ml
gave
approximately
50% survival and the percentage
of
survivors increased to an average of 77% by 24-h
posttreatment.
Although a large concentration of lonidamine and
a long exposure time is required to decrease survival
in MOL T-4 cells. samples viewed in the transmission
electron microscope
show morphological
damage at
doses that do not cause significant cell killing.
The
cells exposed to 50 µg/ml
(Fig. 1) and 200 µg/ml
(Fig. 2) for 1 h show disrupted mitochondria.
The
swollen mitochondria are near the cell surface and, in
some cases, they break through the surface.
The
treated cells have debris on their surface ( arrows in
Figs. 1 and 2). The cell surface also has a swollen
appearance
with fewer surface
ruffles
and more
microvilli
than the controls.
Fig. 3 shows
an
untreated cell after 1 h in medium at pH 6. 7. The
mitochondria
are well formed with visible cristae.
The surface is not as smooth as in the treated cells.
When the MOL T-4 cells are treated
at pH 7.4
(Fig. 4) there is some slight swelling of the mitochondria (arrow), but most are similar to those seen in
the controls.

~

MOL T-4 T-lymphocytes
were exposed
to
lonidamine for 1 h at pH 7.4 and pH 6. 7 followed by
a 24-h incubation in fresh medium at pH 7.4.
Since
survival measured
by trypan blue staining or flow
cytometry gave similar results, the experiments
using
both methods were pooled.
Table 1 gives the relative
survival
levels of
MOL T-4 cells
after
1-h exposure
to various
concentrations of lonidamine. Measurements of survival
immediately after the exposure (not shown) showed
no decrease in survival at either pH or lonidamine
concentration tested.
High drug concentrations,
up to
200 µg/ml,
did not cause very much cell death at
24 h after the exposure.
At 200 µg/ml.
cell survival
averaged
90% in cells treated
at pH 6.7.
The
exposures were carried out at low pH because work
by Kim et al. (1984) has shown that in some cell
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MOL T-4 survival after a 6-h lonidamine

No posttreatment

pH 7.4

et al.

exposure

incubation

24-h incubation

% Survival*

Number of
experiments

Control

99 ± 0.6

6

99 ±

1.1

6

50 µg/mL

98 ± 1.0

6

83 ±

9.6

6

100 µg/mL

92 ± 3.6

6

72 ±

8.5

6

150 µg/mL

77 ± 8.1

6

47 ± 12.4

6

Treatment

pH 6.7

Raaphorst,

% Survival

Number of
experiments

Control

100

6

100

6

50 µg/mL

100 ± 0.3

3

100

3

100 µg/mL

99 ± 0.9

3

99 ±

0.6

3

150 µg/mL

96 ± 2.3

3

89 ±

3.2

3

* Normalized to pH 7.4 control

TABLE 3.

MOL T-4 survival after a 24-h lonidamine

No posttreatment

Treatment
pH 6.7

pH 7.4

incubation

% Survival*

Number of
experiments

exposure

24-h incubation

% Survival

Number of
experiments

Control

93

±

7.0

4

100

2

25 µg/mL

89

±

8.7

4

96

2

50 µg/mL

73

±

10.3

4

78

2

100 µg/mL

53

±

19.7

4

77

2

100

1

100

2

25 µg/mL

98

1

100

2

50 µg/mL

99

1

100

1

100 µg/mL

100

1

93

1

Control

* Normalized to pH 7.4 control
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Fig. 3. A control
medium at pH 6.7

Fig. 1. A transmission electron micrograph of MOLT4 cells exposed to 50 µg/mL lonidamine for 1 h at
pH 6.7. Swollen mitochondria are shown by arrows.

MOL T-4 cell sham-treated

with

Fig. 4.
A MOL T-4 cell exposed
to 50 µg/mL
lonidamine for 1 h at pH 7.4.
The mitochondria
(arrow) are slightly swollen, but the cristae remain
well formed.
These mitochondria
may be compared
to those shown in Fig. 1. There the cells were given
the same treatment except the pH was 6. 7.

Fig. 2. A transmission
electron
micrograph
of a
MOL T-4 cell exposed to 200 µg/mL lonidamine for
1 h at pH 6. 7. Swollen mitochondria are shown by
arrows.

The cell surface can be effectively observed with
the scanning electron microscope.
Figs. Sa and Sb
are control MOL T-4 cells, which were incubated
in
medium at pH 7.4 and pH 6.7, respectively.
MOL T-4
cells are generally spherical with broad ridges over
their surface.
Some cells, however, show a uropod
structure as described by Bessis (1977) along with
multiple ruffles and small filaments.
Cells incubated
for 1 h at pH 6. 7 have more surface projections and
ruffles than the pH 7.4 control.
After a 1-h exposure

to 50 µg/mL lonidamine at pH 6.7 (Fig. 6), the cell
surface still looks similar to the pH 6. 7 control.
In
general, the SEM views of treated and pH 6.7 control
cells were similar.
Only the 200 µg/mL lonidaminetreated sample had extracellular debris and disrupted
microvilli on the surface.
When
cells
that
lonidamine are incubated
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Fig. 6.
A MOL T-4 cell exposed
lonidamine for 1 h at pH 6.7.

to

50 µg/mL

Fig. 5. Scanning electron micrographs of control cells
sham-treated
with medium at (a) pH 7.4 and (b)
pH 6.7.
Fig. 7. A MOL T-4 cell exposed
to 200 µg/ m L
lonidamine
for 1 h at pH 6.7, followed
by 1-h
incubation in fresh medium at pH 7.4.

for 1 h, the cell surface regains the appearance
of
pH 7.4 control cells with the exception of some long
projections.
The 200 µg/mL
lonidamine-treated
sample (Fig. 7) also shows some remaining cellular
debris (arrow).
In the TEM, the return to a normal
morphology is seen more easily.
After a 1-h incubation at pH 7.4, the mitochondrial
swelling
has
decreased dramatically and the cristae have reformed
to a great extent.
The 50 µg/mL lonidamine-treated
sample (Fig. 8) looks very similar to the control and
the 200 µg/mL-treated sample (Fig. 9) has only a few
swollen mitochondria.
The numbers of long, thin
projections seen in the SEM, are visible in the TEM
sections (Figs. 8 and 9) along with some extracellular
debris.

Glioma cells, U-87 MG, have also been tested
for lonidamine toxicity.
Since they grow as attached
cells, the more stringent method of colony counting
was used.
A summary
of U-87 MG survival
is
shown in Table 4. The values are normalized to the
plating efficiency of control cells exposed at pH 7.4.
After a 1-h exposure to 50 µg/mL at pH 6.65, the
relative survival
fell to 91 % of the control
and
decreased to 84% after a 2-h exposure.
As with
MOL T-4 cells, there is a strong pH dependence of the
lonidamine-induced killing. Long exposures of 8 h at
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TABLE 4. Survival of U-87 MG glioma cells after
a lonidamine exposure

pH

7.4
7.4
7.4
7.4
7.4
7.4
7.2
7.0
7.0
6.65
6.65
Fig. 8.
A transmission
electron
micrograph
of a
MOL T-4 cell exposed to 50 µg/mL lonidamine for 1 h
at pH 6.7, followed by a 1-h incubation
in fresh
medium at pH 7.4.

Concentration
(µg/mL)
50
50
50
10
10
10
50
50
50
50
50

*Normalized

Time
(h)
1
2
8
1
2
8
2
1
2
1
2

Survival*

%
100
100
86
100
100
84
97
95
84
91
84

:t

8.6

:t

5.6
3.1
2.1
5.1
3.6
8.7

:t
:t
:t
:t
:t

to pH 7.4 control

Fig. 9.
A MOL T-4 cell exposed
to 200 µg/mL
lonidamine at pH 6.7 followed by a 1-h incubation in
fresh medium at pH 7.4.

Fig. 10. A transmission
electron micrograph
control
U-87 MG glioma cell sham-treated
medium at pH 6. 7 for 1 h.

lower concentrations
of lonidamine
also did not decrease survival greatly.
Thus, U-87 MG glioma cells
are not very sensitive
to lonidamine
under these
conditions.
At the ultrastructural
level the glioma cells are
less reactive to the drug than are MOL T-4.
The
glioma cells are large with many vacuoles,
residual
bodies and lysosomes.
The mitochondria
are small
and not well defined in the micrographs (Fig. 10).

After a 1-h exposure to concentrations
of up to
50 µg/mL lonidamine at pH 6.7, there was no visible
difference between treated and control cells.
After an
1-h exposure to 200 µg/mL lonidamine at pH 6.6, the
endoplasmic reticulum and mitochondria were swollen
(Fig. 11), but they returned to their usual morphology
after a 1-h incubation
in fresh medium at pH 7.4
(Fig. 12).
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A U-87 MG g!ioma
cell exposed
lonidamine at pH 6.7 for 1 h.

Fig. 12.
A U-87 MG glioma
cell exposed
200 µg/mL lonidamine at pH 6.7 for 1 h followed
a 1-h incubation at pH 7.4 in fresh medium.

to

to
by

In the scanning electron microscope views, there
were no visible differences noted between the control
cells and those treated at pH 7.4 or pH 6.7 (Figs. 13
a-d).
The glioma cells were flat, thin cells, with
many microvilli on their surface.
Thus, by morphological assessment the glioma cells were little affected
by lonidamine.
This correlated with the small effect
of the drug on survival.
Discussion
Although
lonidamine
anticancer agent in humans.

Raaphorst,

et al.

in all in vitro test systems (De Martino et al. 1984).
In human and murine lymphocytes,
lonidamine
is
reported to be more effective in B and null leukemia
than in T-cell leukemia (Natali et al. 1984; Floridi
et al. 1981b).
The MOL T-4 cells were selected as a
test system for lonidamine because they are a leukemia that carries a number of T-cell markers. including
surface markers for sheep red blood cell rosetting.
They die by apoptotic
death
similar
to normal
lymphocytes and they are radiation
sensitive,
which
makes them of interest for studies involving synergism
between radiation,
heat or lonidamine
(Minowada
et al. 1972; Szekely et al. 1987a; Raaphorst
et al.
1983).
Since it had been reported that brain cells are
not affected by lonidamine (De Martino et al. 1984)
and, since brain tumors are difficult to treat, we also
looked at the effects of lonidamine on a malignant
glioma cell line U-87 MG. These cells grow attached
to the flask with an epithelial-like morphology. in contrast to the free-floating MOL T-4 cells.
Glioma cells
are relatively radioresistant;
hence, it is of interest to
compare their response to lonidamine with that of the
radiosensitive MOL T-4 cells.
The survival results showed many MOL T-4 and
U-87 MG cells surviving the lonidamine
treatment
even when the dose was large compared to the plasma level achievable in humans (Hahn et al. 1984).
Although the MOL T-4 and U-87 MG cells were
relatively insensitive to lonidamine, they both showed
a strong pH dependence of cell death and morphological change.
This increased
cell death at low pH
agrees with reports on other cell types ( Kim et al.
1984; Stryker and Gerweck, 1988).
This fact is especia I ly important
since
one of the suspected
mechanisms of hypothermic killing in tumors is due to
the lower pH level within the center of the tumor.
Combined lonidamine and hyperthermia treatments
are
being tried and these results suggest a synergism
is
possible.
For both MOL T-4 and glioma cells there
was no significant
cell killing at pH 7.4 even after
6 h of exposure to the drug.
In the electron micrographs it was clear that in
MOL T-4 ultrastructural
damage of the mitochondria
took place within a 1-h exposure to lonidamine
at
pH 6. 7.
There was also some slight damage
at
pH 7.4.
The mitochondria,
however,
regained
a
structure very close to the control within 1 h after
the cells were returned to normal medium at pH 7.4.
Therefore,
the relative
resistance
of MOL T-4 to
lonidamine, as compared to lymphocytes or Ehrlich tumor cells ( Natali et al. 1984; Arancia et a I. 1988;
Floridi et al. 1981b). may be explained by the MOLT4 cells rapid return to a normal ultrastructure
after
removal of the drug.
The rapid return of the ultrastructure
to a normal
appearance
suggests
that
lonidamine should be present at its maximum concen-

1.0~m •

Fig. 11.
200 µg/mL

G. Peter

is being tested
as an
it is not equally effective
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(a)

{b)

(d)

Fig. 13. Scanning electron micrographs of U-87 MG cells treated for 1 h.
(a) Control cell
sham-treated at pH 7.4, (b) control cell sham-treated at pH 6.7, (c) 50 µg/ml lonidamine-treated
cell exposed at pH 6.7 and (d) 200 µg/mL lonidamine-treated cell exposed at pH 6.7.

that already reported.
The only additional factor was
the large number of residual bodies we observed in
our culture conditions. Since the glioma cells were not
greatly altered by lonidamine in the concentrations
we
used, it is possible that the reduced transport
of
lonidamine across the plasma membrane is a factor,
or that the activation state of the mitochondria was
such that they were not affected by the drug.
It has
been reported that mitochondria
in the condensed
state (111)are disrupted by lonidamine (De Martino et
al. 1984). From our observations, the U-87 MG cells

tration to be of use clinically, either alone or as part
of a combination treatment.
U-87 MG glioma cells, on the other hand, are
not greatly altered by the lonidamine exposure.
Although some mitochondria swelling was seen at the
highest lonidamine concentration used, there was little
difference between control and treated samples in both
the SEM and TEM observations.
The ultrastructural
appearance of cultured glioma cells has been described
earlier (Collins et al. 1979; 1980) and in our hands
the U-87 MG cells had an ultrastructure
similar to
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This reinforces the idea that various
a range of response to the drug and
efficiency in cancer treatment
may be
These data indicate
the necessity
lonidamine responses for all types of
for clinical trials of lonidamine therapy.

and MOL T-4 cells do not show the condensed
structure characteristic of mitochondria,
which are actively producing energy.
In our control micrographs
at pH 6.7 or pH 7.4, the mitochondria
have an
expanded morphology with visible finger-like cristae.
Although lonidamine does not dramatically reduce
viability in all cell types, such as the MOL T-4 or U87 MG, the oxidative stress produced by the drug
during and shortly after the exposure suggests
that
lonidamine may be a useful treatment
in conjunction
with X-irradiation, hyperthermia or chemotherapy
with
other drugs.
Thus, even if tumor cells do not
respond to lonidamine directly, they may show synergistic killing in combined treatments.
In fact, glioma
cells have shown enhanced cell killing during combined
lonidamine-hyperthermia
treatment
( data
to be
published elsewhere).
Although the ultrastructure
of
the nucleus was not altered by lonidamine, there are
reports that it inhibits the repair of sublethal damage
in some cell types (Kim et al. 1986; Hahn et al.
1984), but not in all (Danjoux et al. 1988).
The fact that lonidamine is more active at low
pH also suggests that it will be valuable in combination with heat or irradiation.
Solid tumors frequently
have a hypoxic core, which is at a lower pH than the
rest of the tumor.
The rapid growth of tumor cells
also makes the center of solid tumors more acidic.
Thus, the likelihood that lonidamine will interact synergistica IIy with hyperthermia
or irradiation
is
increased.
In our observations
of MOL T-4 and U-87 MG
we have not seen any large blebs or blistering of the
plasma membrane as reported by De Martino et al.
(1984).
Lonidamine does have an effect on molecular
transport across the outer mitochondrial
membrane,
however, as reflected by its ability to increase the response of tumor cells to adriamycin
(Floridi et al.
1987; Starace
et al. 1987; Bagnato
et al. 1987).
Differential effects of lonidamine have also been shown
by the freeze fracture technique (Aranda et al. 1988).
They report
a dose-dependent
clustering
of
intramembrane
particles in lymphocytes
and leukemic
cells.

cell types show
that lonidamine
site dependent.
of evaluating
tumors targeted
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Discussion

With Reviewers

U.T. Brunk:
Would you please expand on the type
of oxidative stress you suggest
is produced by the
drugs?
Are formation of oxygen-derived
free radicals
involved?
Authors:
We concur with the widely held view that
lonidamine acts primarily in the condensed
mitochondria as an inhibitor of the aerobic glycolytic pathway.
In cancer cells there is an increased
glycolytic flux
due to their higher energy
requirements.
It is
suggested by many workers that lonidamine
inhibits
aerobic lactate production by inhibiting the action of
mitochondrially bound hexokinase, which is present in
the outer mitochondria
membrane of neoplastic cells.
Floridi and Lehninger
(1983)
also suggest
that
lonidamine
inhibits electron transport
in the NAOlinked dehydrogenase
system.
The drug produces an
inhibition of oxygen uptake by cultured cells, which
increases dramatically at low pH (Stryker and Gerweck
1988).
In conjunction
with hyperthermia,
lonidamine
may act synergistically
because condensed mitochondria are produced
from the imbalance
in energy
requirements
and the reduced oxygen supply induced
by the heat treatment.
Evidence suggests
that
lonidamine acts by biochemical disruption
of oxygen
utilization and energy production,
and not by a free
radical mechanism.
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acidic for 12 h after heating.
Fellenz and Gerweck
(1988) have shown that intracellular pH depends on
extracellular pH and that thermal sensitivity is closely
related to internal
pH.
Since the vasculature
in
normal tissues is usually resistant to heat relative to
the vasculature in tumors (Song et al. 1980), a synergistic effect between lonidamine and heat is expected.

H. Gamliel: For the various modes of analysis, U-87
MG cells were grown
in flasks,
and/or
glass
coverslips, and/or in dishes.
Can you provide data to
support your assumption that they grow the same on
all these kinds of substrates?
Why did you not use
the widely acceptable, special type of Petri dish with
an inner lining that can serve for SEM, TEM, LM,
etc.? Why did you not embed cells while attached to
the substrate?
Authors:
The flasks and dishes are made from the
same material and have the same surface treatment.
Large numbers of dishes are required for the survival
experiments and hence, specialized dishes would not
be practical for that use. Flasks are the most convenient vehicle for long-term culture of the cell stocks.
In retrospect,
the inner linings you suggest
would
have been ideal for the microscopy
part of the
experiment; however, we did not consider them at the
time. We are satisfied that, since control and treated
cells are being compared, any effect of the glass substrate
(if one exists)
would be common
to both
samples.

H. Gamliel: MOL T-4 cells, under our hands displayed
villous surfaces, as did many other lymphoid leukemia
cell lines.
The SEM pictures provided
show cells
which could be categorized as suffering from air drying (displaying only ridges and undulating
surfaces).
Why did you have to add sucrose to your fixation
solution?
If osmolarity is the issue, it is now well
established that the osmolarity of the vehicle (Hank's
buffer) is more important than the total osmolarity of
the fixative solution.
Fixation with glutaraldehyde
alone is not sufficient, and osmium tetroxide
should
be used also to prevent
massive
shrinkage
of
specimens
and other artifacts
of CPD.
Did you
compare your results with other methods using better
fixation procedures, e.g., TAO, GTGO, etc.?
Authors:
We have tried various buffer-glutaraldehyde
combinations
and have
found
that
the
4%
glutaraldehyde
in Hank's balanced salt solution plus
0.04 mol/L sucrose
suggested
by Abugaber
et al.
(1981) gave good preservation of MOL T-4 cells.
As
they and you point out, buffer osmolarity is more important than that of the fixative, since the cell membrane is not very osmotically active to glutaraldehyde.
In our hands,
the
buffer
and
buffer
plus
glutaraldehyde fixative had osmolarities
of 340 mosm
and 775 mosm, respectively.
We used this combination as our basic fixative and did not try any other.

H.Gamliel: Long exposure to lonidamine seems to be
not less important
than concentration.
Thus, it is
not clear why no data is provided on the exposure of
U-87 MG for 24 h, the most useful time to test, as
indicated with MOL T-4.
Authors:
One purpose of the experiments
was to
compare the survival and morphology of MOL T-4 and
U87-MG after lonidamine
exposure
with results
published with other cell lines.
The shorter drug exposure times of 1 h to 8 h were chosen to correspond with experiments published by other workers on
other cell culture systems
(see text reference list).
Since in vivo exposures are much longer than this, we
decided to extend some MOL T-4 experiments to 24 h.

M. Albertsson:
Are there any measurements
available
on how lonidamine
penetrates
into the hypoxic
tumor's
core
when
administered
orally
or
intravenously?
What about penetration
in the brain
tumor?
Authors:
We are not aware of any human data on
the distribution of lonidamine within tumors.
One of
us (G.P.R.) is collecting biopsy material from patients
treated with lonidamine to monitor its concentration in
various
organs
and tumors.
In rats
lower
concentrations
with respect
to the plasma
are
observed
in most organs.
Only kidney and liver
concentrations
approach the plasma value.
The concentration of lonidamine in the brain is generally low.

H. Gamliel: Why is it so important to show sensitivity at pH 6. 7? - although briefly discussed, it is not
clear how in practice such a low pH can be achieved
in-vivo (beside the point that the "center of solid
tumors is more acidic")?
Why "the likelihood that
lonidamine
will interact
synergistically
with
hyperthermia
or irradiation
is increased"?
Is there
evidence that hyperthermia
or radiation increases the
acidity of tumor cells?
Authors:
Tumor growth relies on the supply of
nutrients and drainage of waste by a functional vascular network. The generally higher level of metabolism
in the oxygenated portion of the tumor and cell death
in the center of a solid tumor produces an acidic environment.
Heat or radiation causes vascular damage
in tumors, which may lead to a nutritionally deprived,
waste-product-rich
and hence acidic environment.
For
example, Rhee et al. (1984) showed that the intrinsically acidic intratumor
environment
became further
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